Using microbubbles to enhance liver cancer treatment with radioembolization
Microbubble Cavitation for Improving Hepatocellular Carcinoma Radioembolization
This study is exploring a new way to make radioembolization treatment for liver cancer more effective by using ultrasound to help deliver radiation better, which could lead to improved results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10834872 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve the effectiveness of radioembolization for treating hepatocellular carcinoma (HCC) by using ultrasound-triggered microbubble destruction. The technique involves administering ultrasound contrast agents that create microbubbles, which, when destroyed by ultrasound, can enhance the delivery of radiation to the tumor. This method aims to increase the sensitivity of cancerous tissue to radiation therapy, potentially leading to better treatment outcomes. Patients undergoing radioembolization may experience improved tumor response and earlier indicators of treatment effectiveness through this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who are undergoing radioembolization treatment.
Not a fit: Patients with early-stage liver cancer who are not candidates for radioembolization may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for liver cancer, improving patient outcomes and survival rates.
How similar studies have performed: Previous research has shown promising results using similar techniques to enhance the effectiveness of cancer treatments, indicating potential for success in this approach.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Eisenbrey, John — Thomas Jefferson University
- Study coordinator: Eisenbrey, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.